Eli Lilly’s Alzheimer’s therapy, donanemab, has received FDA approval, offering new hope for patients with early symptomatic Alzheimer’s disease. The newly approved treatment, branded Kisunla, is set to challenge existing therapies from Eisai and Biogen.  Clinical trials have shown Kisunla to be effective for individuals in the mild cognitive impairment or mild dementia stages of […] Continue reading ->
GENEVA – Partnerships between industry, multilateral organizations, and other stakeholders are essential to overcoming challenges and improving access to innovations. This was the key message at an International Federation of Pharmaceutical Manufacturers (IFPMA) event on Tuesday evening, held on the sidelines of the World Health Assembly in Geneva. The gathering brought together representatives from the […] Continue reading ->
The rising cost of healthcare is one of the most significant burdens on countries, especially low- and middle-income countries. Research has shown that self-care can be critical in reducing unnecessary expenses for healthcare systems. Global self-care activities generate substantial monetary and healthcare workforce savings, totalling at least approximately $119 billion per year, according to a […] Continue reading ->
Three years ago, Dr. Garry Aslanyan searched for a global health podcast he wanted to listen to. When he could not find one, he decided to start his own. “I like podcasts as a tool in other areas, such as politics and current affairs,” Aslanyan told Health Policy Watch. “Podcasts allow for the most open […] Continue reading ->
A team of researchers from the Nuffield Department of Clinical Neurosciences at the University of Oxford have identified diabetes, traffic-related air pollution exposures and alcohol use as the most harmful out of 15 modifiable risk factors for dementia. Their paper, published last month in Nature Communications, examines how genetic traits and modifiable risk factors affect […] Continue reading ->